Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 4:56 AM
Ignite Modification Date: 2025-12-25 @ 4:56 AM
NCT ID: NCT00538018
Eligibility Criteria: Inclusion Criteria: * Adult outpatients with mild to moderate CAP. Diagnosis of CAP was based on the presence of fever and/or hyperleucocytosis and the new and sudden onset of at least two clinical signs and symptoms of pneumonia (cough, dyspnea or tachypnea, chills, pleuritic chest pain, purulent sputum or change in sputum character, auscultatory findings). Clinical diagnosis of CAP had to be confirmed by chest X-ray findings (e.g. presence of presumably new infiltrate). Specimens for microbiological documentation had to be collected within 24 hours prior to enrollment. Exclusion Criteria: * Subjects requiring parenteral antibiotic treatment. * Subjects with severe CAP requiring hospitalization. The CAP was to be considered as severe in the presence of any of the following conditions: * chest X-ray showing a multilobar consolidation (\> 1 lobe)3 and/ or an increase in the size of the opacity by greater than or = to 50% within 48 hours of the current evaluation * shock * altered mental status (disorientation to person, place or time that is not known to be chronic, lethargy, stupor or coma) * total peripheral white blood cell count \< 4,000/mm3 * requirement for mechanical ventilation * requirement for vasopressors * acute renal failure The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT00538018
Study Brief:
Protocol Section: NCT00538018